Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.

Suave hair and beauty brand getting new home in US and Canada at private equity firm Yellow Wood Partners, which plans to grow line through innovation, marketing and distribution. Unilever maintains ownership in other regions.

Reckitt's identification of Cronobacter sakazakii as contaminant in its 145,000-can Enfamil recall is latest clear statement about Cronobacter bacteria potentially disrupting supply of formula and other nutritionals distributed in powder form.